Gus Attridge — Aspen Pharmacare — South African tycoon — Johannesburg Stock Exchange — South Africa — Hot News
Aspen’s market slump wipes $52 million from South African tycoon Gus Attridge’s stake
Attridge, who serves as the group’s chief advisor, holds a 4.3-percent stake in the Durban-based pharmaceutical giant, amounting to 19,033,829 shares.
Related
South African tycoon Gus Attridge’s Aspen stake rebounds above $100 million
Gus Attridge’s Aspen stake rebounds above $100 million as shares recover on the JSE, easing losses after a tough year.
South African tycoon Gus Attridge’s Aspen stake rebounds above $100 million
South African businessman Gus Attridge’s stake in Aspen Pharmacare rebounds above $100 million as the company’s shares recover on the JSE.
South African pharma tycoon Gus Attridge loses $15.8 million on Aspen stake
Aspen co-founder Gus Attridge loses $15.8 million in three weeks as drug stocks fall, cutting Aspen’s value below $2.6 billion.
South African pharma tycoon Gus Attridge loses $12 million from Aspen stake
Gus Attridge’s Aspen Pharmacare stake drops over $12 million as shares slide 9.45%, pushing market value below $3 billion.
Latest
May & Baker returns to profit; billionaire Danjuma family remains controlling shareholder
May & Baker Nigeria’s late year rebound pushed earnings higher in 2025, while the TY Danjuma family maintained a controlling stake.
Nigerian businessman Aderemi Makanjuola’s Caverton posts sharp Q4 revenue drop as quarterly loss narrows slightly
Caverton Offshore Support Group reported a steep Q4 revenue slide to 3.74 billion naira as its net loss eased.
Nigerian billionaire Femi Otedola now owns 18.12% stake in First HoldCo
Femi Otedola has raised his combined stake in First HoldCo to 18.12%, adding to his influence in a major banking group.
The £2 Million Question: What Really Happened at Harrods? How the Diezani Alison-Madueke trial became a masterclass in narrative inflation
On trial in London, Diezani Alison Madueke is cast as a symbol of graft. Her defenders say the story has often outrun the evidence.